Education, Science, Technology, Innovation and Life
Open Access
Sign In
  1. Home
  2. Journals
  3. MEDS Chinese Medicine
  4. Vol 5, Issue 1, 2023

Study on the theory and prescription of pulmonary interstitial fibrosis in Traditional Chinese Medicine

Download as PDF

DOI: 10.23977/medcm.2023.050108 | Downloads: 13 | Views: 432

Author(s)

Meng Fangfang 1, Li Yaohui 2, Wang Yan 1, Zhai Xuejuan 1

Affiliation(s)

1 Shaanxi University of Traditional Chinese Medicine, Xianyang, Shaanxi, 712046, China
2 Shaanxi Hospital of Traditional Chinese Medicine, Xi'an, Shaanxi, 710000, China

Corresponding Author

Meng Fangfang

ABSTRACT

Pulmonary interstitial fibrosis (PIF) is a chronic progressive fibrotic interstitial inflammatory lung disease. The pathogenesis and pathogenesis of PIF are still unclear and there is a lack of effective treatment. As the incidence of PIF increases year by year, the mortality of PIF is not optimistic This paper will summarize the TCM theories related to pulmonary interstitial fibrosis excavated from HowNet database and draw the following conclusions: the theoretical understanding of pulmonary interstitial fibrosis includes the following: lung collaterals, toxic damage to lung collaterals, fire subduing yin collaterals, triple energizer gasification, yin deficiency and blood stasis, Xuanfu theory, yang transforming qi and yin forming, lung being blood viscera; Study on single medicine of traditional Chinese medicine, such as Hongqi, earthworm, Astragalus, Polygonum cuspidatum and other ancient prescriptions, such as Maimendong Decoction, Xiefei Decoction and Yang, and Tang physician prescriptions, such as Qidong Huoxue Yin Feixian Prescription, can effectively delay pulmonary interstitial fibrosis.

KEYWORDS

Pulmonary interstitial fibrosis; Traditional Chinese medicine; Theoretical research; Prescription

CITE THIS PAPER

Meng Fangfang, Li Yaohui, Wang Yan, Zhai Xuejuan, Study on the theory and prescription of pulmonary interstitial fibrosis in Traditional Chinese Medicine. MEDS Chinese Medicine (2023) Vol. 5: 53-60. DOI: http://dx.doi.org/10.23977/medcm.2023.050108.

REFERENCES

[1] Wang Zhimei, Ma Zhanping, Li Meng. Clinical treatment of pulmonary interstitial fibrosis by famous old Chinese medicine practitioners [J]. World Latest Medical Information Digest, 2017, 17 (34): 159-160.
[2] Dong Chunying, Zhang Yi, Yu Xueqing. Discussion on TCM disease names of pulmonary interstitial fibrosis [J]. Chinese Medicine Research, 2016, 29(09):3-6.
[3] Zhang Yaoyi, Pang Lijian. Discussion on the different stages of pulmonary fibrosis based on the syndrome and treatment system of lung collaterals Pathogenesis [J]. Chinese Medicine Clinic, 2022, 34(04):603-607.
[4] He Jinfang, Zhang Yi, Zhang Di, etc. Discussion on TCM treatment of idiopathic pulmonary fibrosis from "micro-mass of lung collaterals" [J]. Journal of Traditional Chinese Medicine, 2022, 37 (03): 507-510.
[5] Su Jian, Zhang Wei. Discussion on the pathogenesis and treatment of idiopathic pulmonary interstitial fibrosis based on the theory of accumulation and dispersion of lung collaterals [J]. Chinese Medicine, 2021, 62 (11): 947-950 +970.
[6] Li Wen, Liu Rongkui, Diao Enjun. Treating pulmonary interstitial fibrosis from toxin and evil [J]. Shandong Traditional Chinese Medicine, 2021, 40 (02): 186-189.
[7] Zhang Yongsheng, Kang Xinyue, Li Yongming, etc. Theoretical construction and treatment ideas of "toxic damage to lung collaterals" in chronic lung diseases [J]. Traditional Chinese Medicine, 2016, 57 (11): 927-929.
[8] Huang Lina, Zhang Wei. Treatment of pulmonary interstitial fibrosis from toxic damage to lung collaterals [J]. Shi Zhen Chinese Medicine, 2018, 29 (05): 1150-1151.
[9] Ran Weizheng, Chen Zhigang. The necessity of classification of collaterals from the perspective of "prolonged illness entering the collaterals" [J]. Basic Medicine of Traditional Chinese Medicine, 2019, 25(07):883-884+981.
[10] Bi Zhangyang, Yang Fan, Zhang Wei. Discussion on the evolution and treatment of pulmonary interstitial fibrosis in TCM pathogenesis and treatment from the perspective of "fire and yin collaterals"[J].Journal of Liaoning University of Traditional Chinese Medicine, 2021, 23(01):63-66.
[11] Xu Niannian, Xiong Xiuping. Brief introduction of Miao Xiyong's thought of reducing qi [J]. Herald of Traditional Chinese Medicine, 2016, 22 (10): 117-118.
[12] Yu Jianwei, Xue Hanrong, Zhang Yuanbing, etc. Professor Hong Guangxiang, a master of traditional Chinese medicine, gathered academic thoughts on the diagnosis and treatment of pulmonary diseases [J]. Zhonghua Chinese Medicine, 2015, 30(11):3824-3829.
[13] Chen Feng, Zhang Wei. Discussion on idiopathic pulmonary interstitial fibrosis based on the "Sanjiao gasification theory" [J]. Chinese Medicine, 2020, 61(14):1238-1241.
[14] Lan Zhihui, Zhang Yuanbing, Li Shaofeng, etc. Professor Liu Liangzhu used Wenfei Huaxian Decoction to treat pulmonary interstitial fibrosis [J]. Chinese Traditional Medicine, 2014, 29 (10): 3141-3143.
[15] Ran Dawei. Triple energizer syndrome differentiation is used for heart understanding of lung diseases [J]. Jiangsu Traditional Chinese Medicine, 2016, 48 (10): 95-97.
[16] Feng Yu, Zhou Dandan, Xiao Qingling, etc. Treatment of pulmonary interstitial fibrosis from yin deficiency and blood stasis [J]. Acta Traditional Chinese Medicine, 2020, 48 (03): 64-66.
[17] Huang Yuanke, Li Hong. Modern research on the mechanism of Xuanfu theory on the treatment of idiopathic pulmonary interstitial fibrosis [J]. Gansu Science and Technology Zongheng, 2020, 49(02):1-3.
[18] Tian Li, Zhang Wei. Interpulmonary medicine based on the theory of "yang transforms qi, yin forms" Discussion on the pathogenesis and treatment of fibrosis [J]. Shizhen Guoyi Guoyao, 2019, 30(03):647-648.
[19] Wang Qingjun, Li Ping, Liu Xiao. A randomized controlled study on treating 80 patients with idiopathic pulmonary interstitial fibrosis with Wenyang Huayu method [J]. China Continuing Medical Education, 2016, 8(03): 193-196.
[20] Lan Zhihui, Zhang Yuanbing, Li Shaofeng, et al. Professor Liu Liangxi used Wenfei Huaxian Decoction to treat pulmonary interstitial fibrosis [J]. Zhonghua Traditional Chinese Medicine, 2014, 29(10):3141-3143.
[21] Yuan Chengbo, Wang Tan, Shi Li. Modified Xiaoqinglong Decoction in the treatment of pulmonary interstitial fibrosis [J]. Journal of Changchun University of Traditional Chinese Medicine, 2014, 30(04):640-641+644.
[22] Lefrancaid E, Ortiz-Munoz G, Caudrilier A, et al. The lung is a site of platelet biogenesis and a reservoir for haematopietic progenitors. Nature, 2017, 544: 105-109.
[23] Ji Hong, He Huanyu, Shen Yun, et al. Exploring the effect of activating blood circulation and removing blood stasis prescription on glycosylation modification of TGF-β/Smad2/3 transduction pathway in pulmonary interstitial fibrosis [J]. Zhonghua Chinese Medicine, 2014, 29(03):727-731.
[24] Huang Lina, Zhang Wei. Discussion on blood stasis and pulmonary interstitium from the perspective of "lungs as blood organs" Fibrosis relationship [J]. Zhonghua Traditional Chinese Medicine, 2018, 33(09): 3859-3861.
[25] Pang Yuhan, Wang Tong, Li Ruili. Study on the treatment of pulmonary fibrosis with 8 effective components of traditional Chinese medicine [J]. Jilin Traditional Chinese Medicine, 2017, 37 (09): 952-954 +965.
[26] Wang Yi, Li Juan, et al. Effects of Astragalus polysaccharides, Astragalus flavonoids and Astragalus saponins against bleomycin-induced pulmonary interstitial fibrosis in rats [J]. Chinese Patent Medicine, 2022, 44(02):573-578.
[27] Yang Jingjin. Earthworm extract weakens silica dust-induced Research on the mechanism of pulmonary fibrosis in mice [D]. Nanjing Medical University, 2016.
[28] Zhu Mingting, Wu Yuexin, Zuo Yan. Observation on the therapeutic effect of modified Maimendong Decoction on patients with pulmonary interstitial fibrosis [J]. Clinical studies such as World Integrated Traditional Chinese and Western Medicine, 2021, 16 (10): 18-1873.
[29] Liu Bao, Hu Xingang, Zhao Limin, et al. Study on Maimendong Decoction Inhibiting Cell Oxidative Damage in Idiopathic Pulmonary Interstitial Fibrosis by PPAR γ [J]. Chinese Traditional Medicine, 2019, 34 (11): 5136-5140.
[30] An Fangyu, Yan Chunlu, Liu Yongqi, etc. Intervention of Xiefei Decoction on TGF-β 1/Smads Transduction Pathway in Rats with Pulmonary Fibrosis [J]. Chinese Traditional Medicine, 2018, 33 (06): 2641-2645.
[31] Liu Xiangyu, Li Yiliang, Ge Yanlei, etc. Clinical Observation on Idiopathic Pulmonary Interstitial Fibrosis Treated by Ginger-separated Du Moxibustion Combined with Yanghe Decoction [J]. Yunnan Traditional Chinese Medicine, 2021, 42 (05): 31-34.
[32] Song Dongsheng, Zhou Qingwei, Cui Weifeng. Modified Mufangji Decoction combined with traditional Chinese medicine iontophoresis in the treatment of diffuse qi deficiency and phlegm stasis type Clinical research on chronic pulmonary interstitial fibrosis [J]. New Chinese Medicine, 2022, 54(12): 60-65.
[33] Xu Liying, Cai Wanru, Wang Huishang, etc. Clinical application of Qidong Huoxue Yin in treating pulmonary interstitial fibrosis [J]. Journal of Zhejiang University of Traditional Chinese Medicine, 2022, 46 (02): 148-151.
[34] Dong Huan, Zhang Xiaomei, Meng Lihong, et al. Effect of Feixian Recipe on Epithelial-mesenchymal Transition in Rats with Pulmonary Interstitial Fibrosis Induced by Bleomycin [J]. Chinese Traditional Medicine, 2020, 35 (02): 862-865.
[35] Cai Xuan, Lei, Wang Hao, Jin Peipei, Shen Xiaohua, Su Kuiguo. Professor Su Kuiguo's treatment of pulmonary interstitial fibrosis [J]. Western Chinese Medicine, 2021, 34 (05): 46-49.
[36] Li Zhenhua. Progress in diagnosis and treatment of idiopathic pulmonary interstitial fibrosis [J]. Chinese Practical Internal Medicine, 2020, 40 (05): 353-356.
[37] Bing Lin, Bai Huihui. Clinical observation on oral administration of traditional Chinese medicine combined with iontophoresis in the treatment of diffuse pulmonary interstitial fibrosis [J]. Practical Chinese Medicine, 2018, 34 (05): 515-516. 

Subscription
E-Mail Alert
Most popular papers
Call for Special Issue
Publication Ethics & OA Statement
Plagiarism Policy
Contact Us
Downloads: 4203
Visits: 165797

Sponsors, Associates, and Links

All published work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2016 - 2031 Clausius Scientific Press Inc. All Rights Reserved.